Judy R. Joice Net Worth

The estimated Net Worth of Judy R Joice is at least $556 Thousand dollars as of 14 May 2021. Ms Joice owns over 60,137 units of Durect Corp stock worth over $149,101 and over the last 11 years she sold DRRX stock worth over $0. In addition, she makes $406,510 as Sr. VP of Operations & Corp. Quality Assurance at Durect Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms Joice DRRX stock SEC Form 4 insiders trading

Ms has made over 2 trades of the Durect Corp stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 60,137 units of DRRX stock worth $45,704 on 14 May 2021.

The largest trade she's ever made was exercising 60,137 units of Durect Corp stock on 14 May 2021 worth over $45,704. On average, Ms trades about 9,830 units every 29 days since 2014. As of 14 May 2021 she still owns at least 94,969 units of Durect Corp stock.

You can see the complete history of Ms Joice stock trades at the bottom of the page.

Ms. Judy R. Joice biography

Judy R. Joice is the Sr. VP of Operations & Corp. Quality Assurance at Durect Corp.

What is the salary of Ms Joice?

As the Sr. VP of Operations & Corp. Quality Assurance of Durect Corp, the total compensation of Ms Joice at Durect Corp is $406,510. There are 3 executives at Durect Corp getting paid more, with Dr. James E. Brown D.V.M. having the highest compensation of $775,884.

How old is Ms Joice?

Ms Joice is 64, she's been the Sr. VP of Operations & Corp. Quality Assurance of Durect Corp since . There are 2 older and 2 younger executives at Durect Corp. The oldest executive at Durect Corp is Dr. Su Il Yum Ph.D., 82, who is the Exec. Officer.

What's Ms Joice's mailing address?

Judy's mailing address filed with the SEC is C/O DURECT CORPORATION, 10260 BUBB ROAD, CUPERTINO, CA, 95014.

Insiders trading at Durect Corp

Over the last 21 years, insiders at Durect Corp have traded over $528,010 worth of Durect Corp stock and bought 19,954,650 units worth $23,296,708 . The most active insiders traders include April Fund Ltd21 April Fund..., Eagle Investment Management..., and Felix Theeuwes. On average, Durect Corp executives and independent directors trade stock every 55 days with the average trade being worth of $468,485. The most recent stock trade was executed by Judith J. Robertson on 18 August 2022, trading 80,942 units of DRRX stock currently worth $68,801.

What does Durect Corp do?

durect is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. durect’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. late stage development programs of this nature include remoxy® and posidur™. durect’s epigenomic regulator program includes the lead molecule dur-928 in phase 1 clinical testing. dur-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. for more information, please visit www.durect.com. we also manufacture and sell two commercial product lines: • alzet® osmotic pumps use

Complete history of Ms Joice stock trades at Durect Corp

Durect Corp executives and stock owners

Durect Corp executives and other stock owners filed with the SEC include:

• Dr. James E. Brown D.V.M.,
  Co-Founder, CEO, Pres & Director
• Michael H. Arenberg,
  CFO & Sec.
• Dr. Norman L. Sussman,
  Chief Medical Officer
• Judy R. Joice,
  Sr. VP of Operations & Corp. Quality Assurance
• Dr. Su Il Yum Ph.D.,
  Exec. Officer
• Jian Li M.B.A.,
  VP of Fin. & Corp. Controller
• Dr. WeiQi Lin,
  Exec. VP of R&D and Principal Scientist
• Steve Helmer J.D.,
  VP & Chief Patent Counsel
• Dr. Andrew R. Miksztal,
  VP of Pharmaceutical R&D and Principal Scientist
• Judy R Joice,
  Sr. VP Operations & Corp QA
• April Fund Ltd21 April Fund...,
  
• April Fund Ltd Arnhold & S....,
  
• Dave Hoffmann,
  Director
• Jon S Saxe,
  Director
• Terrence F Blaschke,
  Director
• Jay Shepard,
  Director
• Armand Neukermans,
  Director
• Simon X Benito,
  Director
• Eagle Investment Management...,
  
• April Fund Ltd21 April Fund...,
  
• Matthew J Hogan,
  Chief Financial Officer
• Michael Arenberg,
  Chief Financial Officer
• Judith J. Robertson,
  Director
• Gail M Farfel,
  Director
• Paula V Mendenhall,
  Sr. VP of Operations
• Su Il Yum,
  Exec. VP Pharm./R&D
• Michael D Casey,
  Director
• Joseph William Stauffer,
  CMO and Exec.VP Corp. Strategy
• Jean I Liu,
  Senior VP & General Counsel
• Edward M Gillis,
  VP Engineering
• Thomas A Schreck,
  Chief Financial Officer
• Michael J Taylor,
  VP, Non Clinical Research
• Felix Theeuwes,
  Chairman and CSO
• Arthur J Tipton,
  Sr.VP Bioerodible Product Dev.
• Timothy S Nelson,
  Senior VP Business & Dev.
• Peter Langecker,
  Chief Medical Officer
• Tai Wah Chan,
  VP Pharmaceutical Research
• Steven Halladay,
  VP Clinical and Regulatory
• Li Jian,
  VP Finance and Controller
• Lp Bleichroeder,
  10% owner
• Eagle Investment Management...,
  
• Mohammad Azab,
  Director
• Gail J Maderis,
  Director
• Peter S Garcia,
  Director
• James E Brown,
  President & CEO
• Timothy M. Papp,
  Chief Financial Officer
• Norman Sussman,
  Chief Medical Officer